Technetium Tc-99m pertechnetate

Identification

Logo pink
Are you a
new drug developer?
Contact us to learn more about our customized products and solutions.
Name
Technetium Tc-99m pertechnetate
Accession Number
DB09314  (DB13043)
Type
Small Molecule
Groups
Approved, Investigational
Description

Technetium Tc-99m pertechnetate is a radiopharmaceutical diagnostic agent composed of an oxoanion with the chemical formula TcO4-. Pertechnetate has a wide variety of uses within nuclear medicine as it distributes within the body to a similar extent as iodine. It also concentrates in the thyroid gland, salivary glands, gastric mucosa, and choroid plexus. However, in contrast to the iodide ion, the pertechnetate ion is released unchanged from the thyroid gland. Currently marketed as the product Drytec, technetium-99m pertechnetate is indicated for imaging of the following tissues: thyroid, salivary gland, urinary bladder (for detection of vesico-ureteral reflux), and the nasolacrimal drainage system.

Technetium-99m's short half life (6 hours) makes storage impossible, therefore it is supplied as its parent nuclide molybdenum-99, which spontaneously decays to technetium-99 through beta decay. This is normally supplied in a hospital setting through the use of a technetium-99m generator, whereby technetium exits the generator in the form of the pertechnetate ion, TcO4−, which can be extracted and promptly used for clinical diagnostics. Following intravenous injection, single photon emission computed tomography (SPECT) is performed to detect the gamma ray emmitted by the decay of Technetium-99m to Technetium-99.

Structure
Thumb
Synonyms
  • (99Tc)pertechnetate
  • CPERT
  • GPERT
  • Pertechnetate-99Tc
  • Technetium (99mTc) Pertechnetate
  • Technetium Tc 99m Pertechnetate
Product Ingredients
IngredientUNIICASInChI Key
Technetium Tc-99m sodium pertechnetateA0730CX80123288-60-0MKADDTFVKFMZGF-UHFFFAOYSA-N
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Drytec (Technetium Tc99m Generator)Kit811 mCi/1mLMedi-Physics Inc.2014-04-01Not applicableUs
Drytec (Technetium Tc99m Generator)Kit270 mCi/1mLMedi-Physics Inc.2014-04-01Not applicableUs
Drytec (Technetium Tc99m Generator)Kit135 mCi/1mLMedi-Physics Inc.2014-04-01Not applicableUs
Drytec (Technetium Tc99m Generator)Kit2027 mCi/1mLMedi-Physics Inc.2014-04-01Not applicableUs
Drytec (Technetium Tc99m Generator)Kit676 mCi/1mLMedi-Physics Inc.2014-04-01Not applicableUs
Drytec (Technetium Tc99m Generator)Kit243 mCi/1mLMedi-Physics Inc.2014-04-01Not applicableUs
Drytec (Technetium Tc99m Generator)Kit108 mCi/1mLMedi-Physics Inc.2014-04-01Not applicableUs
Drytec (Technetium Tc99m Generator)Kit1622 mCi/1mLMedi-Physics Inc.2014-04-01Not applicableUs
Drytec (Technetium Tc99m Generator)Kit541 mCi/1mLMedi-Physics Inc.2014-04-01Not applicableUs
Drytec (Technetium Tc99m Generator)Kit230 mCi/1mLMedi-Physics Inc.2014-04-01Not applicableUs
Additional Data Available
  • Application Number
    Application Number

    A unique ID assigned by the FDA when a product is submitted for approval by the labeller.

    Learn more
  • Product Code
    Product Code

    A governmentally-recognized ID which uniquely identifies the product within its regulatory market.

    Learn more
Categories
UNII
PPP8783IQ1
CAS number
23288-61-1
Weight
Average: 169.968
Monoisotopic: 169.95002301
Chemical Formula
H8O4Tc
InChI Key
ZTFPRNKAHXDALS-RCUQKECRSA-N
InChI
InChI=1S/4H2O.Tc/h4*1H2;/q;;;;-1/i;;;;1+1
IUPAC Name
tetrahydrate (98Tc)technetiumuide
SMILES
O.O.O.O.[98Tc-]

Pharmacology

Indication

Sodium Pertechnetate Tc99m Injection is indicated for use in adults for imaging in the following tissues: thyroid, salivary gland, urinary bladder (for detection of vesico-ureteral reflux), and nasolacrimal drainage system (dacryoscintigraphy). It is indicated for use in children for imaging the following tissues: thyroid and urinary bladder.

Associated Conditions
Pharmacodynamics
Not Available
Mechanism of action

The pertechnetate ion distributes in the body similarly to the iodide ion, but is not organified when trapped in the thyroid gland. It also concentrates in the thyroid gland, salivary glands, gastric mucosa, and choroid plexus. However, in contrast to the iodide ion, the pertechnetate ion is released unchanged from the thyroid gland.

Additional Data Available
Adverse Effects

Comprehensive structured data on known drug adverse effects with statistical prevalence. MedDRA and ICD10 ids are provided for adverse effect conditions and symptoms.

Learn more
Additional Data Available
Contraindications

Structured data covering drug contraindications. Each contraindication describes a scenario in which the drug is not to be used. Includes restrictions on co-administration, contraindicated populations, and more.

Learn more
Additional Data Available
Blackbox Warnings

Structured data representing warnings from the black box section of drug labels. These warnings cover important and dangerous risks, contraindications, or adverse effects.

Learn more
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
Not Available
Food Interactions
Not Available

References

General References
  1. Ryo UY, Vaidya PV, Schneider AB, Bekerman C, Pinsky SM: Thyroid imaging agents: a comparison of I-123 and Tc-99m pertechnetate. Radiology. 1983 Sep;148(3):819-22. [PubMed:6308711]
External Links
KEGG Drug
D08761
PubChem Compound
131709156
PubChem Substance
310265199
ChEMBL
CHEMBL2109884
Wikipedia
Pertechnetate
ATC Codes
V09FX01 — Technetium (99mtc) pertechnetate

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1CompletedDiagnosticNeoplasms, Thyroid1
1SuspendedTreatmentEndometrial Clear Cell Adenocarcinoma / Endometrial Mixed Adenocarcinoma / Endometrial Serous Adenocarcinoma / Endometrial Undifferentiated Carcinoma / Metastatic Endometrioid Adenocarcinoma / Ovarian Endometrioid Adenocarcinoma / Recurrent Endometrial Serous Adenocarcinoma / Recurrent Uterine Corpus Carcinoma / Stage IV Uterine Corpus Cancer / Stage IVA Uterine Corpus Cancer / Stage IVB Uterine Corpus Cancer1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
FormRouteStrength
Kit108 mCi/1mL
Kit1081 mCi/1mL
Kit135 mCi/1mL
Kit1351 mCi/1mL
Kit162 mCi/1mL
Kit1622 mCi/1mL
Kit2027 mCi/1mL
Kit203 mCi/1mL
Kit230 mCi/1mL
Kit243 mCi/1mL
Kit270 mCi/1mL
Kit2703 mCi/1mL
Kit338 mCi/1mL
Kit405 mCi/1mL
Kit541 mCi/1mL
Kit676 mCi/1mL
Kit68 mCi/1mL
Kit811 mCi/1mL
InjectionIntravenous; Intravesical; Ophthalmic6 Ci/6Ci
Injection, solutionIntravenous250 mCi/1mL
Injection, solutionIntravenous1 Ci/1
Injection, solutionIntravenous1.5 Ci/1
Injection, solutionIntravenous11 Ci/1
Injection, solutionIntravenous14 Ci/1
Injection, solutionIntravenous16 Ci/1
Injection, solutionIntravenous19 Ci/1
Injection, solutionIntravenous2 Ci/1
Injection, solutionIntravenous2.5 Ci/1
Injection, solutionIntravenous3 Ci/1
Injection, solutionIntravenous3.5 Ci/1
Injection, solutionIntravenous5 Ci/1
Injection, solutionIntravenous6 Ci/1
Injection, solutionIntravenous7.5 Ci/1
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility137.0 mg/mLALOGPS
logP-1.4ALOGPS
logP-0.65ChemAxon
logS0.61ALOGPS
pKa (Strongest Acidic)15.7ChemAxon
pKa (Strongest Basic)-1.8ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count1ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area25.3 Å2ChemAxon
Rotatable Bond Count0ChemAxon
Refractivity3.7 m3·mol-1ChemAxon
Polarizability1.51 Å3ChemAxon
Number of Rings0ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterNoChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
Not Available

Taxonomy

Classification
Not classified

Drug created on November 16, 2015 15:49 / Updated on June 04, 2019 07:11